Back
Spero Therapeutics Quote, Financials, Valuation and Earnings
Invest. Do Good. Get Rewarded. Just $0.26/Share!
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
16
SPRO
Spero Therapeutics
Last Price:
1.18
Seasonality Move:
6.24%
7 Day Trial
ALL ACCESS PASS
$
7
Say this - unlock as much as $1,250 every Friday
Click here for full details.Spero Therapeutics Price Quote
$1.18
-0.01 (-0.84%)
(Updated: November 22, 2024 at 5:55 PM ET)
Spero Therapeutics Key Stats
Sell
16
Spero Therapeutics (SPRO)
is a Sell
Day range:
$1.15 - $1.21
52-week range:
$1.01 - $1.89
Dividend yield:
0%
P/E ratio:
2.77
P/S ratio:
0.71
P/B ratio:
0.99%
Volume:
193.5K
Avg. volume:
343.4K
1-year change:
-1.65%
Market cap:
$64.9M
Revenue:
$96.7M
EPS:
$0.08
How Much Does Spero Therapeutics Make?
-
How Much Are Spero Therapeutics's Sales Annually?
SPRO Revenues are $96.7M -
How Much Profit Does Spero Therapeutics's Make A Year?
SPRO net income is $22.8M
Is Spero Therapeutics Growing As A Company?
-
What Is Spero Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.67% -
What Is Spero Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Spero Therapeutics Stock Price Performance
-
Did Spero Therapeutics Stock Go Up Last Month?
Spero Therapeutics share price went down by -7.03% last month -
Did SPRO's Share Price Rise Over The Last Year?
SPRO share price fell by -1.65% over the past 1 year
What Is Spero Therapeutics 52-Week High & Low?
-
What Is Spero Therapeutics’s 52-Week High Share Price?
Spero Therapeutics has traded as high as $1.89 over the past 52 weeks -
What Is Spero Therapeutics’s 52-Week Low Share Price?
Spero Therapeutics has traded as low as $1.01 over the past 52 weeks
Spero Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Spero Therapeutics?
-
How Much Debt Does Spero Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Spero Therapeutics Have?
Cash and short term investments quarterly total is $76.3M -
What Is Spero Therapeutics’s Book Value Per Share?
Book value per share is 1.21
Is Spero Therapeutics Cash Flow Positive?
-
What Is SPRO Cash Flow From Operations?
Cash flow from operations (TTM) is -$17.5M -
What Is Spero Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $0 -
What Is Spero Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is $0
Spero Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
SPRO return on invested capital is 4.36% -
What Is Spero Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is 2.37% -
What Is SPRO Return On Equity?
ROE is a measure of profitability and is 4.36%
Spero Therapeutics Earnings Date & Stock Price
-
What Is Spero Therapeutics's Stock Price Today?
A single share of SPRO can be purchased today for 1.19 -
What Is Spero Therapeutics’s Stock Symbol?
Spero Therapeutics trades on the nasdaq under the ticker symbol: SPRO -
When Is Spero Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Spero Therapeutics is scheduled on March 13, 2025 -
When Is SPRO's next ex-dividend date?
Spero Therapeutics's next ex-dividend date is September 16, 2015 -
How To Buy Spero Therapeutics Stock?
You can buy Spero Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Spero Therapeutics Competitors
-
Who Are Spero Therapeutics's Competitors?
Below is a list of companies who compete with Spero Therapeutics or are related in some way:
Spero Therapeutics Dividend Yield
-
What Is SPRO Dividend Yield?
Spero Therapeutics’s dividend yield currently is 0% -
What Is Spero Therapeutics’s Payout Ratio?
Spero Therapeutics’s payout ratio is 0% -
When Did Spero Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 23, 2024 -
What Is Spero Therapeutics’s Dividend Per Share?
Spero Therapeutics pays a dividend of $0.00 per share
Spero Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 11.93% |
| Revenue: | -66.56% | 75.68% |
Analyst Recommendations
| Buy Recommendations: | 2 |
|---|---|
| Hold Recommendations: | 1 |
| Sell Recommendations: | 0 |
| Price Target: | 5.00 |
| Upside from Last Price: | 320.17% |